tbuckley/cabot-search huggingface dataset:
Abstract IA21: New technologies to monitor and understand RNA-binding proteins in cancer cells
Authors: Matthias W. Hentze
Journal: Cancer Research (2017)

Abstract Based on the development of “RNA interactome capture”, we recently discovered that hundreds of cellular proteins, previously well known for other biological functions, also unexpectedly bind RNA (termed “enigmRBPs” for enigmatic RNA-Binding Proteins) (1-4). Since many enigmRBPs are conserved from yeast to humans, their existence raises pressing questions—for benign as well as for cancer cells. One of the most stunning surprises was the discovery that almost all enzymes of the glycolytic pathway are conserved as enigmRBPs. Overall, more than 50 metabolic enzymes were found to bind RNA. Could the combination of enzymatic and RNA-binding functions represent a general biological principle for coordination between gene expression and metabolism? (5,6). Applying a newly developed technique, RBDmap, to identify the RNA-binding domains of enigmRBPs, we uncovered new RNA-binding architectures yielding functional insights (7). Integrating all information, we discuss a possible new function for genomes in addition to their classical role in driving protein biosynthesis via mRNAs, rRNAs, and tRNAs and their associated modifying and regulatory RNAs. I will also reflect on how RNA interactome capture and RBDmap can advance our understanding of cancer cell biology. (1) Castello et al., Cell 149, 1393-1406, 2012 (2) Castello et al., Nature Protoc. 8, 491-500, 2013 (3) Kwon et al., Nature Struc. Mol. Biol. 20, 1122-1132, 2013 (4) Beckmann et al., Nature Communications, 2015 (5) Hentze and Preiss, TiBS 35, 423-426, 2010 (6) Castello et al., Trends in Endocrin. Metab., 2015 (7) Castello et al., Mol. Cell, 2016 Citation Format: Matthias W. Hentze. New technologies to monitor and understand RNA-binding proteins in cancer cells. [abstract]. In: Proceedings of the AACR Special Conference on Translational Control of Cancer: A New Frontier in Cancer Biology and Therapy; 2016 Oct 27-30; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2017;77(6 Suppl):Abstract nr IA21.
Low viremic HBeAg negative HBsAg carriers: clinical outcome and non invasive diagnostic accuracy for chronic hepatitis B or inactive infection by combinations of HBV markers
Authors: F. Oliveri, L. Surace, D. Cavallone, P. Colombatto, G. Ricco, N. Salvati, B. Coco, V. Romagnoli, R. Gattai, A. Salvati, F. Moriconi, Q. Yuan, F. Bonino, M.R. Brunetto
Journal: Journal of Hepatology (2017)
Rook's Textbook of Dermatology, 9th edn. ChristopherGriffiths, JonathanBarker, TanyaBleiker, RobertChalmers, DanielCreamer, eds. Publisher: Wiley-Blackwell, 2016; 4696 pp. ISBN: 978-1118441190. Price €654.49.
Authors: P.C.M. van de Kerkhof
Journal: British Journal of Dermatology (2017)
Hematopoietic Stem Cells Fail to Regenerate In Vivo Following Inflammatory Stress
Authors: Ruzhica Bogeska, Paul Kaschutnig, Stella Paffenholz, Julia Maassen, Jan-Philipp Mallm, Felix Wertek, Dagmar Walter, Blaszkiewicz Sandra, Tim Holland-Letz, Noboru Asada, Julius Gräsel, Sina Stäble, Milena Block, Özge Gizlenci, Áine M. Prendergast, Simon Haas, Daniel B Lipka, Karsten Rippe, Benedikt Brors, Paul S. Frenette, Marieke A. G. Essers, Michael D. Milsom
Journal: Blood (2016)
Donor mannose-binding lectingene polymorphisms increase the risk of severe bacterial infections after liver transplantation
Authors: J. Lombardo, G. Sanclemente, J. Colmenero, M. Español, M.T. Arias, P. Ruiz, E. Mauro, L. Sastre, G. Crespo, A. Moreno, F. Lozano, M. Navasa
Journal: Journal of Hepatology (2017)
Cloning and characterization of the Fanconi anaemia complementation group F gene.
Authors: J P De Winter, Q Waisfisz, M A Rooimans, L van der Weel, C G M van Berkel, J de Groot, L Bosnoyan-Collins, F Arwert, C G Mathew, R J Scheper, M E Hoatlin, M Buchwald, H Joenje
Journal: Blood (1999)
Neoadjuvant therapy preceding cytoreductive nephrectomy to develop individualized first-line therapy with everolimus for advanced renal cell carcinoma (RCC).
Authors: Guru Sonpavde, Gilad Amiel, Vitaly Margulis, Richard E Link, Seth P. Lerner, Ganesh Raj, Wesley A Mayer, Ganesh S. Palapattu, Yair Lotan, Arthur I. Sagalowsky, Linda C Higgins, Sebrina A Tello, Andrea Pavia-Jimenez, Dendra VonMerveldt, James Brugarolas
Journal: Journal of Clinical Oncology (2012)

TPS4678 Background: Everolimus (E), an orally administered mTOR inhibitor, is the conventional agent for progressive disease following vascular endothelial growth factor (VEGF) inhibitors for advanced RCC. Given the excellent tolerability and convenient oral administration, a rationale may be made to develop E as first-line therapy for selected patients. The period between diagnosis and cytoreductive nephrectomy (CN) may be utilized for brief therapy to capture biologic activity in tumor tissue and facilitate individualized systemic therapy. The agent may be resumed following CN and continued until progression. Pharmacodynamic (PD) alterations from baseline to CN tumor tissue may predict progression-free survival (PFS). We hypothesized that the application of this paradigm to E may enable the employment of first-line E in patients predicted to optimally benefit. Methods: This is a 27-patient phase II trial being conducted at the Baylor College of Medicine and University of Texas Southwestern, and 5 patients have been enrolled currently. Patients with ≥3 poor risk factors or those who refuse or are ineligible for VEGF inhibitors and have untreated metastatic RCC are eligible. Adequate hematologic, renal and hepatic function is required. The primary endpoint is PFS and secondary endpoints are response, survival and toxicities. Exploratory endpoints are tumor tissue, peripheral blood mononuclear cell (PBMC) and plasma PD studies and pharmacokinetic (PK) studies, and their association with PFS. PD studies include DNA, mRNA, protein and miRNA studies to evaluate the mTORC1 among other pathways. Patients initially undergo 4 core biopsies of the primary renal mass for fresh frozen tumor. Patients then receive E 10 mg orally once daily for 3-5 weeks. CN is performed within 24-48 hours after the last dose of E. At the time of CN and before separation from the vascular supply, 3 core biopsies are performed. E is resumed 2-4 weeks after CN and continued until progression or intolerable toxicities. Clinical and laboratory assessments are performed every 4-5 weeks, and imaging is performed every 8 weeks. A progressing metastatic site will be biopsied (4 core biopsies).
Correlation between prevalence of hepatitis B and C virus infection and mortality of hepatocellular carcinoma in Uvs province, Mongolia
Authors: U. Baatarsuren, T. Munkh-Erdene, M. Myanganbayar, M. Batsukh, A. Jamsranjav, D. Dugerjav, O. Tseren, C. Janchiv, A. Bungert, A. Dagvadorj, E. Enkhbayar, N. Dashdorj, Z. Genden, N. Dashdorj
Journal: Journal of Hepatology (2017)
Preclinical evaluation of polyethylenimine-mediated RNA interference of Polo-Like Kinase 1 gene for ultrasound image-guided treatment of hepatocellular carcinoma
Authors: E. Heuillard, G.B. About, M. Goncalves, F. Gosse, V. Lindner, T. Sorg, R. Memeo, Y. Herault, P. Erbacher, P. Pessaux, T.F. Baumert, E. Robinet
Journal: Journal of Hepatology (2017)
Effect of pregnant sera and a pregnancy-associated metalloproteinase (PAPP-A) on melanoma in vitro and in vivo: Insights into melanoma progression during pregnancy and potential new therapeutic targets.
Authors: Prashanth Prithviraj, Matthew Anaka, Andreas Behren, Aparna Jayachandran, Jonathan S. Cebon
Journal: Journal of Clinical Oncology (2014)

9063 Background: At 45/105pregnancies, Malignant Melanoma (MM) is the commonest cancer diagnosed in pregnant women. An aggressive course & poor outcomes are recognised to occur during pregnancy. IGF1 plays an important role in embryogenesis & cancer progression. IGF1 circulates as a complex with IGFBP4, which is cleaved by Pregnancy-Associated Plasma Protein-A (PAPP-A), resulting in release of IGF1. PAPP-A serum levels increase exponentially during pregnancy. Methods: 8 MM cell lines were cultured with pregnant & normal sera. Effect on proliferation (MTS) & invasion/migration (wound healing & matrigel transwell assays) were analysed. PAPP-A expression in human MM & cell lines was analysed by PCR, ELISA & IHC. Transient siRNA knock-down of PAPP-A & downstream gene/protein expression were confirmed. Functional assays were performed after PAPP-A knockdown at 24, 48 & 72hrs. An avian neural crest cell migration assay was used to confirm effects in-vivo. Furthermore, effect of PAPP-A neutralising Ab on cell motility & migration induced by sera was analysed. Results: PAPP-A is widely expressed in MM tumors and cell lines. While the proliferation of MM cells did not change with PAPP-A knockdown, migratory & invasive capacity was significantly decreased (>40% p<0.05). This effect was confirmed in-vivo. The neutralizing Ab attenuated invasion and migration of MM cells, confirming the knockdown results. PAPP-A levels in pregnant sera were 70-fold higher than in control sera. Treatment of MM cells with this serum led to decreased proliferation, but enhanced migration & invasion of MM cells in-vitro. Using an antibody against PAPP-A to evaluate its role in this, we detected a reversion of pregnant serum-induced invasion and migration. Conclusions: Pregnant sera enhances the migratory & invasive behaviour of MM cells in-vitro, which can be effectively attenuated by Ab against PAPP-A. Reduced invasion & migration after PAPP-A knockdown suggests a potential therapeutic target in treatment of MM. This study also gives an indication towards a biological mechanism (PAPP-A) involved in MM progression during pregnancy.
Indirubin-3’-monoxim induced apoptosis in human tumor cells via pro-apoptotic Bcl-2 family members
Authors: Jie Shi, Han-Ming Shen
Journal: Clinical Cancer Research (2007)

B46  Indirubin is the active component of an anticancer drug treating chronic myelogenous leukemia in Chinese medicine. Indirubin-3’-monoxime (I3M) and other indirubin derivatives have been known for their anti-tumor activity and have the potential to develop anti-cancer agents due to their specific cytotoxicity to cancer cells, efficacy in vivo, and ability to potentiate other apoptosis-inducing agents. I3M has been well-established as a cyclin-dependent kinase inhibitor, while the molecular mechanism underlying I3M-induced apoptosis has not been fully elucidated. In this study, we focused on the involvement of the Bcl-2 family members in I3M-induced apoptosis. We first observed I3M -induced apoptosis in a time- and dose-dependent manner in three different types of human cancer cells - cervical cancer HeLa, hepatoma HepG2 and colon cancer HCT116. Induction of the caspase cascade for both the extrinsic and intrinsic pathways was demonstrated, including caspase-8, caspase-9 and caspase-3 activation. Interestingly, we found that caspase-8 activation resulted in Bid cleavage, followed by Bax conformational change, and cytochrome c release. Stable knockdown of Bid blocked I3M-induced Bax conformational change and apoptosis. In addition, ectopic expressions of a viral caspase inhibitor (CrmA) or Bcl-2 partially protected I3M-induced apoptosis. In conclusion, our results indicate that I3M-induced apoptosis recruited both death receptor and mitochondrial pathways and the pro-apoptotic Bcl-2 family members (Bid and Bax) play a critical role in mediating the crosstalk between the above pathways, and hence provide the basis for future development of I3M and other indirubins into cancer therapeutic agents.
Lawyers plan class action against UK government on asthma caused by air pollution
Authors: Susan Mayor
Journal: BMJ (2017)

Lawyers are planning a class action against the UK government on behalf of people with asthma caused by air pollution.

The class action, which will be led by barrister Frances Lawson, is bringing a state liability claim against the government, arguing that people have had symptoms of asthma because of a failure to reduce air pollution …
Inappropriate Comparator Group in Study of Selective Serotonin Reuptake Inhibitors and Risk for Intracranial Hemorrhage—Reply
Authors: Christel Renoux, Sophie Dell’Aniello, Jean-François Boivin
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Hepatitis B patients under oral nucleos(t)ide treatment with intermittent kidney function assessment (The BONIKA-study) – a multicenter, prospective, observational trial (NCT-Nr. 02267473)
Authors: K. Sprinzl, S. Steinhoff, S. von Hatzfeldt, J. Vermehren, T. Welzel, A. Grambihler, A. Weinmann, E. Herrmann, P.R. Galle, S. Zeuzem, M.F. Sprinzl, C. Sarrazin
Journal: Journal of Hepatology (2017)
Abstract 100: An Altered Epigenomic Mark Predisposes to Dilated Cardiomyopathy Through Alternative Splicing of Sarcomeric Gene Expression in Mice
Authors: Ana Vujic, Emma Robinson, Mitsutero Ito, Syed Haider, Jeremy Skepper, Carmen Methner, Anne Ferguson-Smith, Roger Foo
Journal: Circulation Research (2012)

Distinct epigenomic patterns of DNA methylation exist in important elements of the cardiac genome in human end-stage cardiomyopathy but whether these contribute to disease progression is unknown. We examined and found that the main DNA methyltransferase expressed in the adult mammalian heart is DNMT3B. We therefore generated a conditional inducible Dnmt3b knockout mouse to test the effect of altered DNA methylation in the heart. Upon induction in the adult mouse, Dnmt3b knockout (CKO) led rapidly to severe systolic insufficiency and myocardial thinning. Examination of myocyte nuclei reflected a loss of homogeniety and re-distribution of heterochromatin. This was accompanied by widespread myocardial interstitial fibrosis and myofibrillary disarray. We examined the myocardial transcriptome of CKO mice by RNA-seq and discovered significant changes in levels of transcript splicing isoforms especially those of sarcomeric genes. When subjected to pressure overload, CKO mice failed to mount a compensatory hypertrophic response and instead developed accelerated fulminant dilated cardiomyopathy. Our results demonstrate that DNA methylation has a distinct role with regulating transcript isoform splicing apart from gene expression. In particular, we have highlighted a mechanism by which the epigenome may mediate the development and progression of a complex disease.
Portosystemic shunts in cirrhosis are associated to more complications and deteriorated quality of life: an international cohort study
Authors: M. Simón-Talero, D. Roccarina, A. Majumdar, E.A. Tsochatzis, J. Martínez, C. Picón, A. Albillos, K. Lampichler, D. Toth, T. Reiberger, A. Baiges, A. Darnell, V. Hernandez-Gea, G. Low, J.G. Abraldes, P. Tandon, E. Llop, M. Lopez, J.L. Calleja, M. Praktiknjo, G. Kukuk, J. Trebicka, M. Maurer, A. Berzigotti, A. Zipprich, C. Ripoll, M. Triolo, V. La Mura, G. Vangrinsven, W. Laleman, R. Garcia-Martinez, R. Bañares, A. Dam, A. Krag, S. Augustin, J. Genescà
Journal: Journal of Hepatology (2017)
Transcription factors SOHLH1 and SOHLH2 coordinate oocyte differentiation without affecting meiosis I
Authors: Yong-Hyun Shin, Yu Ren, Hitomi Suzuki, Kayla J. Golnoski, Hyo won Ahn, Vasil Mico, Aleksandar Rajkovic
Journal: Journal of Clinical Investigation (2017)

Following migration of primordial germ cells to the genital ridge, oogonia undergo several rounds of mitotic division and enter meiosis at approximately E13.5. Most oocytes arrest in the dictyate (diplotene) stage of meiosis circa E18.5. The genes necessary to drive oocyte differentiation in parallel with meiosis are unknown. Here, we have investigated whether expression of spermatogenesis and oogenesis bHLH transcription factor 1 (Sohlh1) and Sohlh2 coordinates oocyte differentiation within the embryonic ovary. We found that SOHLH2 protein was expressed in the mouse germline as early as E12.5 and preceded SOHLH1 protein expression, which occurred circa E15.5. SOHLH1 protein appearance at E15.5 correlated with SOHLH2 translocation from the cytoplasm into the nucleus and was dependent on SOHLH1 expression. NOBOX oogenesis homeobox (NOBOX) and LIM homeobox protein 8 (LHX8), two important regulators of postnatal oogenesis, were coexpressed with SOHLH1. Single deficiency of Sohlh1 or Sohlh2 disrupted the expression of LHX8 and NOBOX in the embryonic gonad without affecting meiosis. Sohlh1-KO infertility was rescued by conditional expression of the Sohlh1 transgene after the onset of meiosis. However, Sohlh1 or Sohlh2 transgene expression could not rescue Sohlh2-KO infertility due to a lack of Sohlh1 or Sohlh2 expression in rescued mice. Our results indicate that Sohlh1 and Sohlh2 are essential regulators of oocyte differentiation but do not affect meiosis I.
Correlation of molecular status and anatomic sites of metastases (mets) at diagnosis (Dx) of non-small cell lung cancer (NSCLC)
Authors: C. Kuijpers, L. Hendriks, J. Derks, A.-M. Dingemans, A. Van Lindert, M. Van den Heuvel, R. Damhuis, S. Willems
Journal: Annals of Oncology (2017)
Workplace-Based Investigation of Contacts of a Patient With Highly Infectious Tuberculosis—Maryland, District of Columbia, and Virginia, 2006
Authors: E Munk, G Maltas, S Dorman, B Johnson, S Johnson, K Taylor, J Thomas, C Campbell, Baltimore County, Health Dept, L Gossett, M Mentzer, Anne County, Y Richards, T Walsh, Montgomery County, S Massey, L Federline, K Trimeloni, Prince George's County, E Balm, J Douge, Frederick County, M Miner, C Goldsbor- Ough, M Donovan, W Cronin, D Blythe, V Randle, J Moore, W Heirendt, S Keller, W White, M Tipple, D Hardge, J Hinnant, G Mirchandani
Journal: JAMA (2008)

Incorrect CME Quiz Question in: Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk
ASTRIS: A multicenter, real world treatment study of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC)
Authors: P.K. Cheema, Y.-M. Chen, F. de Marinis, H.C. Freitas, S.-W. Kim, A. Milner, M. Provencio, J. Rigas, Y.-L. Wu
Journal: Annals of Oncology (2017)
Non-invasive tools to ruling out large varices: RESIST-HCV vs. Baveno VI criteria in a large cohort of patients with HCV cirrhosis
Authors: V. Calvaruso, I. Cacciola, A. Licata, S. Madonia, R. Benigno, F. Bronte, S. Petta, G. Malizia, G. Bertino, M. Di Stefano, R. Volpes, A. Montineri, A. Di Giacomo, G. Alaimo, B. Cacopardo, L. Guarneri, I. Scalisi, G. Mazzola, F. Cartabellotta, V. Portelli, M. Russello, G. Squadrito, G. Raimondo, A. Craxì, V. Di Marco
Journal: Journal of Hepatology (2017)
Different erythromycin-resistant phenotypes of Streptococcus pyogenes do not prevent human polymorphonuclear cells from their antibacterial activity
Authors: G Banche, Tullio, Allizond, N Mandras, J Roana, D Scalas, F El Fassi, S D’Antico, N Carlone, Am Cuffini
Journal: Clinical Microbiology and Infection (2010)
Replacement of the murine common bile duct with a bioengineered conduit incorporating primary human cholangiocyte organoids
Authors: F. Sampaziotis, A.W. Justin, O.C. Tysoe, S. Sawiak, R.L. Gieseck, M.C. de Brito, N.L. Berntsen, M.J. Gomez-Vazquez, D. Ortmann, L. Yiangou, J. Bargehr, A. Bertero, M.C. Zonneveld, M.T. Pedersen, M. Pawlowski, N. Georgakopoulos, N. Pirmadjid, G.M. Skeldon, E.M. Godfrey, W. Shu, P.M. Materek, K.E. Snijders, S.E. Brown, C.A. Rimland, I. Simonic, S. Davies, K. Jensen, W.T. Gelson, G. Alexander, S. Sinha, N.R. Hannan, T. Wynn, T.H. Karlsen, E. Melum, A.E. Markaki, K. Saeb-Parsy, L. Vallier
Journal: Journal of Hepatology (2017)
Dissecting the DNA Repair Machinery in Biological Subgroups of Childhood Acute Lymphoblastic Leukemia
Authors: Nellina Andriano, Valeria Iachelli, Paola Bonaccorso, Manuela La Rosa, Emanuela Cannata, Vito Miraglia, Salvatore D'Amico, Andrea Di Cataldo, Giovanna Russo, Luca Lo Nigro
Journal: Blood (2016)
Screening contacts of patients with extrapulmonary TB for latent TB infection
Authors: Anna Humphreys, Aula Abbara, Sion Williams, Laurence John, Tumena Corrah, Alastair McGregor, Robert N Davidson
Journal: Thorax (2017)

2016 TB National Institute for Health and Care Excellence (NICE) guidelines imply that contacts of extrapulmonary TB do not require screening for latent TB infection. At our high TB prevalence site, we identified 189 active cases of TB for whom there were 698 close contacts. 29.1% of the contacts of pulmonary TB and 10.7% of the contacts of extrapulmonary TB had active or latent TB infection. This supports screening contacts of extrapulmonary TB at our site and presents a way to access high-risk individuals. We propose to continue to screen the contacts of our patients with extrapulmonary TB and recommend other TB units audit their local results.
Successful treatment of patients with HCV GT3 infection and cirrhosis with elbasvir/grazoprevir plus sofosbuvir does not correct insulin resistance by 12 weeks post-treatment
Authors: G. Foster, K. Agarwal, M.E. Cramp, S. Moreea, S. Barclay, J. Collier, A.S. Brown, S.D. Ryder, A. Ustianowski, D.M. Forton, R. Fox, F. Gordon, W.M. Rosenberg, D.J. Mutimer, J. Du, C.L. Gilbert, M. Robertson, E. Barr, B. Haber
Journal: Journal of Hepatology (2017)